Organon will also furnish Dermavant with a $75 million milestone payment contingent upon Vtama’s approval in atopic ...
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
GlobalData on MSN1d
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiaryAs part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed ...
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis We apologize, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback